Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen

J Infect. 2013 Oct;67(4):303-12. doi: 10.1016/j.jinf.2013.05.008. Epub 2013 Jun 22.

Abstract

Introduction: The identification of novel reverse-transcriptase (RT) drug-resistance mutations is critical in predicting the probability of success to anti-HBV treatment. Furthermore, due to HBV-RT/HBsAg gene-overlap, they can have an impact on HBsAg-detection and quantification.

Methods: 356 full-length HBV-RT sequences from 197 drug-naive patients and 159 patients experiencing virological-breakthrough to nucleoside/nucleotide-analogs (NUCs) were analyzed. Mutants and wild-type HBs-antigens were expressed in HuH7-hepatocytes and quantified in cell-supernatants and cell-lysates by Architect HBsAg-assay.

Results: Ten novel RT-mutations (rtN53T-rtS78T-rtS85F-rtS135T-rtA181I-rtA200V-rtK212Q-rtL229V/F-rtM309K) correlated with specific NUC-treatments and classical drug-resistance mutations on divergent evolutionary pathways. Some of them reduced RT-binding affinity for anti-HBV drugs and altered S-antigen structure. Indeed, rtS78T (prevalence: 1.1% in drug-naïve and 12.2% in adefovir-failing patients) decreased the RT-affinity for adefovir more than the classical adefovir-resistance mutations rtA181 T/V (WT:-9.63 kcal/mol, rtA181T:-9.30 kcal/mol, rtA181V:-7.96 kcal/mol, rtS78T:-7.37 kcal/mol). Moreover, rtS78T introduced a stop-codon at HBsAg-position 69, and completely abrogated HBsAg-quantification in both supernatants and cell-lysates, indicating an impaired HBsAg-secretion/production. Furthermore, the HBsAg-mutation sP217L, silent in RT, significantly correlated with M204V/I-related virological-breakthrough and increased HBsAg-quantification in cell-lysate.

Conclusions: Mutations beyond those classically known can affect drug-binding affinity of mutated HBV-RT, and may have potential effects on HBsAg. Their cumulative effect on resistance and HBV-pathogenicity indicates the importance of preventing therapeutic failures.

Keywords: HBV drug-resistance; HBsAg secretion; HBsAg stop codon; HBsAg structure; Treatment failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Adult
  • Cell Line
  • Codon, Nonsense
  • Drug Resistance, Viral
  • Female
  • Gene Expression
  • Hepatitis B / drug therapy*
  • Hepatitis B Surface Antigens / analysis*
  • Hepatitis B Surface Antigens / genetics
  • Hepatitis B virus / drug effects*
  • Hepatocytes / virology
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Organophosphonates / administration & dosage
  • Organophosphonates / pharmacology
  • Protein Binding
  • RNA-Directed DNA Polymerase / genetics*
  • RNA-Directed DNA Polymerase / metabolism
  • Reverse Transcriptase Inhibitors / administration & dosage*
  • Reverse Transcriptase Inhibitors / metabolism
  • Reverse Transcriptase Inhibitors / pharmacology
  • Selection, Genetic
  • Treatment Failure

Substances

  • Codon, Nonsense
  • Hepatitis B Surface Antigens
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • adefovir
  • RNA-Directed DNA Polymerase
  • Adenine